Vemlidy® (tenofovir alafenamide) – New drug approval
November 10, 2016 – Gilead announced the FDA approval of Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Download PDF
